A report in The New Scientist, "Prescribing of Hyperactivity Drugs is Out of Control," shows just how deviant U.S. prescribing of psychostimulants for
children is compared to the rest of the world.
The focus of a recent FDA’s Psychopharmacology Advisory Committee meeting, was the drug, modafinil (as Sparlon), for ADHD and the risk of
Steven-Johnson’s, a rare but potentially fatal, skin condition.
"That thing I’m worried about…where the MedGuide would help, where it might even warrant a black box, if this is common, where somebody hallucinates and then gets put on an anti-psychotic drug. That would really be something worth making sure it doesn’t happen,"
On Wednesday, the FDA Pediatric Advisory Committee handed the agency a mixed message regarding warnings about selective list of
psychotropic drugs prescribed for treating ADHD symptoms.
The Associated Press reports that a just released study that found that a staggering, two and half million children in the U.S. are being prescribed antipsychotics annually–that’s 40 out of every 1,000 children.
Psychiatric Adverse Events Associated with Drug Treatment of ADHD: Review of Postmarketing Safety Data
Children have been dying from exposure to psychostimulant drugs as the FDA looked the other way:
